Drug Profile
Melatonin sublingual - iX Biopharma
Alternative Names: WafeRestLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator iX Biopharma
- Class Anti-inflammatories; Chemoprotectants; Hormones; Radioprotectives; Sleep disorder therapies; Tryptamines
- Mechanism of Action Antioxidants; Melatonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 21 Oct 2020 Discontinued - Phase-III for Sleep disorders in Singapore (Sublingual) (iX Biopharma pipeline, October 2020)
- 21 Sep 2020 iX Biopharma has patent protection for WaferiX™ delivery technology in Israel
- 21 Sep 2020 iX Biopharma has patent protection for WaferiX™ delivery technology in the United States, Israel, China, Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia, and Indonesia, countries in the European Union